Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption

Pelthos Therapeutics

13/08/2026 12:20

Overview
U.S. biopharmaceutical firm's Q2 net product revenue grew 45% quarter-over-quarter
Net loss for Q2 narrowed compared to Q1, adjusted EBITDA loss also improved
Company expenses rose due to milestone payments and inventory write-offs in Q2

Outlook
Pelthos expects further growth for Zelsuvmi, with over 4,200 units dispensed in July
Company plans to commercialize Xepi in Q1 2027 and Xeglyze in Q3 2027
Pelthos believes current cash and potential Horizon facility funds will support its business plan

Result Drivers
ZELSUVMI ADOPTION - Co said growing adoption and increased prescriptions of Zelsuvmi drove Q2 revenue growth
MILESTONE AND ROYALTY EXPENSES - Q2 expenses rose due to two non-recurring sales-based milestones and higher royalty costs
INVENTORY WRITE-OFF - Q2 cost of goods sold included a $0.9 mln write-off of commercial API inventory after quality control testing

Company press release: ID:nGNX5p8TQL

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$23.42 mln
 
Q2 Adjusted EBITDA
 
-$5.70 mln
 
Q2 Operating Income
 
-$17.32 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Pelthos Therapeutics Inc is $55.00, about 90.2% above its August 12 closing price of $28.91

Reuters Recommended Reads
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 12 - Israel's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Aug 12 - Liquidia Q2 revenue jumps on YUTREPIA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)